Please provide your email address to receive an email when new articles are posted on . Retinopathy of prematurity occurs primarily in low birth weight premature infants who are admitted to a neonatal ...
TARRYTOWN, N.Y., April 17, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and its collaborator Bayer today announced that aflibercept 8 mg and EYLEA® (aflibercept) Injection ...
A 0.4 mg dose of aflibercept in infancy to treat retinopathy of prematurity (ROP) shows sustained efficacy and safety at 3 years of age, according to research presented at EURETINA 2024. No ...
This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...
Credit: Getty Images. The approval was based on data from the phase 3 BUTTERFLEYE and FIREFLEYE trials. The Food and Drug Administration (FDA) has approved Eylea ® (aflibercept) for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback